In contrast with desvenlafaxine, the CYP2D6 genetic polymorphism has a significant influence on venlafaxine pharmacokinetics.122 Both drugs may have low potential for drug interactions, because of low protein binding and a relatively weak inhibitory effect on CYP isoenzymes.90,123 Nevertheless, increased plasma levels of imipramine, its metabolite desimipramine,124 and risperidone were associated with concomitant administration of venlafaxine.125 Furthermore, diphenhydramine may alter the disposition of venlafaxine via inhibition of CYP2D6.126 CYP3A4 inducers may enhance the clearance rate of desvenlafaxine.122
|